Centocor Seeks Continuing Damages Over Humira

Law360, New York (January 4, 2010, 4:36 PM EST) -- Centocor Ortho Biotech Inc. has filed a new suit against Abbott Laboratories, seeking continuing damages as Abbott appeals a $1.85 billion judgment that its arthritis treatment Humira infringes a patent held by the Johnson & Johnson unit.

The complaint — filed Dec. 28 in the U.S. District Court for the Eastern District of Texas — seeks actual and enhanced damages based on Abbott's alleged continuing willful infringement of Centocor's patent.

In June 2009, a jury in the same court awarded Centocor $1.17 billion in lost profits...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.